AOCNP Questions with Verified Correct
Answers
Genetic variants assoc with hereditary breast and ovarian cancer
ATTM
BRCA 1 & BRCA2
CHEK2
PALB2
PTEN
TP53
Genetic variants and cancers assoc with Li-Fraumeni
TP53
***Sarcomas
**Breast/colon
brain, adrenocorticol, melanoma, gastric, pancreatic, esophageal, lung
Genetic variants and cancers assoc with Cowden syndrome
PTEN
***Breast/colon
GI, mucocutaneous, thyroid
,Genetic variants and cancers assoc with lynch syndrome
MLH1
MSH2
MSH6
PMS2
EPCAM
***Ovarian, endometrial, colon, prostate, pancreatic
Gastric, biliary, renal, skin, glioblastoma
Genetic variants and cancers assoc with FAP
APC
***Colon
Small bowel, pancreatic, thyroid, CNS, gastic, liver, biliary
Genetic variants and cancers assoc with Peutz-Jehgers
CDKN2A
STK11
***Pancreatic, breast, ovarian, colorectal
GI, testicular, lung
Lynch syndrome screenings
,-Colonoscopy q1-2yr age 20-25 or 2-5 years prior to youngest dx in family
-EGD q2-4yrs age 30-35
-Annual pelvic and endometrial sampling age 30-35 or 5-10 years prior to youngest dx in
family
-TVUS/CA 125 q6-12months
-prophylactic TAH/BSO after childbearing complete
-Skin exam q1-3yr
-If family hx pancreatic CA, annual imaging age 50 or 10 years prior to youngest dx in family
NCCN prostate screening guidelines
BL PSA and possible DRE:
-Age 45-75
-Starting age 40 if Black, FH prostate CA, BRCA2 (can consider for BRCA1)
NCCN breast screening guidelines- average risk
-Age 25-39: breast awareness, clinical encounter q1-3yrs
-Age 40+: breast awareness, annual clinical encounter, annual mammogram
NCCN breast screening guidelines- BRCA1/2
-Clinical breast exam every 6–12 months starting at age 25
-Age 25–29: Annual breast MRI with and without contrast (preferred over mammography
due to radiation concerns); mammogram only if MRI unavailable
-Age 30–75: Annual mammogram + annual breast MRI with and without contrast
-Consider risk reducing surgery or hormone therapy
, NCCN breast screening guidelines- Li Fraumini
TP53
-Clinical breast exam every 6-12 months starting at age 20
-Age 20-29: Annual breast MRI (no mammography due to radiation sensitivity)
-Age 30-75: Annual mammogram + annual breast MRI
NCCN breast screening guidelines- Residual Lifetime Risk ≥20% (by Comprehensive
Family History Models)
-Clinical encounter every 6–12 months, beginning when identified as increased risk
-Annual mammogram with tomosynthesis: beginning no later than age 40, or 10 years
before the youngest affected family member's diagnosis (not before age 30)
-Annual breast MRI with and without contrast: beginning no later than age 40, or 10 years
before the youngest affected family member's diagnosis (not before age 25)
-Consider risk reduction surgery or hormone therapy
NCCN breast screening guidelines- ≥1.7% by Gail Model or Imaging-Based Model
-Clinical encounter every 6–12 months
-Annual mammogram with tomosynthesis (to begin when identified as increased risk)
-Consider annual breast MRI with and without contrast (this is a "consider"
recommendation, not a definitive recommendation as in the ≥20% lifetime risk group)
-Consider risk reduction surgery or hormone therapy
NCCN breast screening guidelines-ADH or Lobular Neoplasia (LCIS/ALH)
-Clinical encounter every 6–12 months starting at diagnosis
Answers
Genetic variants assoc with hereditary breast and ovarian cancer
ATTM
BRCA 1 & BRCA2
CHEK2
PALB2
PTEN
TP53
Genetic variants and cancers assoc with Li-Fraumeni
TP53
***Sarcomas
**Breast/colon
brain, adrenocorticol, melanoma, gastric, pancreatic, esophageal, lung
Genetic variants and cancers assoc with Cowden syndrome
PTEN
***Breast/colon
GI, mucocutaneous, thyroid
,Genetic variants and cancers assoc with lynch syndrome
MLH1
MSH2
MSH6
PMS2
EPCAM
***Ovarian, endometrial, colon, prostate, pancreatic
Gastric, biliary, renal, skin, glioblastoma
Genetic variants and cancers assoc with FAP
APC
***Colon
Small bowel, pancreatic, thyroid, CNS, gastic, liver, biliary
Genetic variants and cancers assoc with Peutz-Jehgers
CDKN2A
STK11
***Pancreatic, breast, ovarian, colorectal
GI, testicular, lung
Lynch syndrome screenings
,-Colonoscopy q1-2yr age 20-25 or 2-5 years prior to youngest dx in family
-EGD q2-4yrs age 30-35
-Annual pelvic and endometrial sampling age 30-35 or 5-10 years prior to youngest dx in
family
-TVUS/CA 125 q6-12months
-prophylactic TAH/BSO after childbearing complete
-Skin exam q1-3yr
-If family hx pancreatic CA, annual imaging age 50 or 10 years prior to youngest dx in family
NCCN prostate screening guidelines
BL PSA and possible DRE:
-Age 45-75
-Starting age 40 if Black, FH prostate CA, BRCA2 (can consider for BRCA1)
NCCN breast screening guidelines- average risk
-Age 25-39: breast awareness, clinical encounter q1-3yrs
-Age 40+: breast awareness, annual clinical encounter, annual mammogram
NCCN breast screening guidelines- BRCA1/2
-Clinical breast exam every 6–12 months starting at age 25
-Age 25–29: Annual breast MRI with and without contrast (preferred over mammography
due to radiation concerns); mammogram only if MRI unavailable
-Age 30–75: Annual mammogram + annual breast MRI with and without contrast
-Consider risk reducing surgery or hormone therapy
, NCCN breast screening guidelines- Li Fraumini
TP53
-Clinical breast exam every 6-12 months starting at age 20
-Age 20-29: Annual breast MRI (no mammography due to radiation sensitivity)
-Age 30-75: Annual mammogram + annual breast MRI
NCCN breast screening guidelines- Residual Lifetime Risk ≥20% (by Comprehensive
Family History Models)
-Clinical encounter every 6–12 months, beginning when identified as increased risk
-Annual mammogram with tomosynthesis: beginning no later than age 40, or 10 years
before the youngest affected family member's diagnosis (not before age 30)
-Annual breast MRI with and without contrast: beginning no later than age 40, or 10 years
before the youngest affected family member's diagnosis (not before age 25)
-Consider risk reduction surgery or hormone therapy
NCCN breast screening guidelines- ≥1.7% by Gail Model or Imaging-Based Model
-Clinical encounter every 6–12 months
-Annual mammogram with tomosynthesis (to begin when identified as increased risk)
-Consider annual breast MRI with and without contrast (this is a "consider"
recommendation, not a definitive recommendation as in the ≥20% lifetime risk group)
-Consider risk reduction surgery or hormone therapy
NCCN breast screening guidelines-ADH or Lobular Neoplasia (LCIS/ALH)
-Clinical encounter every 6–12 months starting at diagnosis
